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Abstract
Background: Human papillomavirus (HPV) is the leading cause of cervical cancer and other malignant and benign
neoplastic lesions. HPV vaccination has three potential goals: to prevent transmission, infection, and disease. At
present, there are no available data about health consequences of HPV immunization in Italy. The aim of this study
is to evaluate the effect of current HPV vaccination strategy in Italy.
Methods: A multistate morbidity-mortality model was developed to estimate the infection process in a theoretical
cohort of Italian women. The Markov process considered nine health states (health, anogenital warts, grade 1 and
grade 2/3 cervical intraepithelial neoplasia, cervical cancer, anal cancer, death due to cervical cancer, anal cancer
and other causes), and 26 transition probabilities for each age group. The model was informed with the available
data in national and international literature. Effectiveness of immunization was assumed considering a literature
review pertaining to models and vaccination coverage rates observed in Italy. Life expectancy (ex), Quality-Adjusted
Life Years (QALYs), Disability-Adjusted Life Years (DALYs), and attributable risk (AR) were estimated for no
intervention (cervical cancer screening) and vaccination strategies scenarios.
Results: The model showed that in a cohort of 100,000 Italian women the e0 is equal to 83.1 years. With current
HPV vaccination strategy the e0 achieves 83.2 (+0.1) years. When HPV-related diseases are considered altogether,
the QALYs increase from 82.7 to 82.9 (+0.2 QALYs) with no intervention and vaccination strategies respectively.
DALYs decrease by 0.6 due to vaccination. Finally, AR is equal to 93 and 265 cases per 100,000 women in
population and not vaccinated, respectively.
Conclusion: When mortality due to cervical cancer is considered, HPV vaccination seems to have a low impact on
health unit gains in the Italian female population. Conversely, when several HPV-related and cancer morbidity
conditions are included, the effect of vaccination becomes quite remarkable.
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Key message
1. The objective of this study is to estimate the impact
of HPV-related diseases on the Italian population, in
terms of health conditions and death risk. Further-
more, it evaluates the role of the Italian prevention
system on health improvement, both in terms of
mortality and morbidity.
2. A multistate morbidity-mortality model was devel-
oped to estimate the infection process in a theoretical
cohort of Italian women. The Markov process took
into consideration nine health states (health, anogeni-
tal warts, grade 1 and grade 2/3 cervical intraepithe-
lial neoplasia, cervical cancer, anal cancer, death due
to cervical cancer, anal cancer and other causes), in
addition to 26 transition probabilities.
3. The results showed that in a cohort of 100,000
Italian women the e0 is equal to 84.31 years. With
current HPV vaccination strategy the e0 achieves
84.36 (+0.05) years. When HPV-related diseases are
considered altogether, the QALYs increase from 83.9
to 84.1 (+0.2 QALYs) with no intervention and
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vaccination strategies respectively. DALYs decrease by
0.6 due to vaccination. Finally, AR is equal to 0.08
and 0.29 in population and not vaccinated,
respectively.
4. At present this work is the first model trying to
evaluate the actual effect of vaccination on women’s
health in Italy. The study considers the actual
vaccination coverage nationwide, along with the
distribution of different types of vaccines at regional
level. It projects a fictitious cohort of women in order
to evaluate the impact on morbidity and mortality
trajectories of these individuals.
Background
Human papillomavirus (HPV) is probably the most com-
mon sexually transmitted viral infection worldwide [1].
It is well established that HPV is the causative factor in
most cases of cervical cancer [2, 3]. High-risk oncogenic
variants of HPV, specifically genotypes 16 and 18, ac-
count for approximately 75% of all cervical carcinomas
[4]. However, HPV is involved both in the etiopathogen-
esis of invasive cervical cancer and in other malignant
and benign neoplastic lesions that affect the vulva,
vagina, anus, penis, head and neck, respiratory tract
[recurrent respiratory papillomatosis (RRP)], and exter-
nal anogenital area (genital warts acuminate) [2, 5–9].
HPV triggers about 600,000 cases of cervical cancer
annually, cancer of the vulva, vagina, anus, penis, head
and neck, as well as non-malignant neoplastic diseases,
such as anogenital warts and recurrent respiratory papil-
lomatosis (RRP), with an impressive medical and eco-
nomic burden [10]. Italian data suggest the total direct
cost associated with the annual incident cases of the
nine HPV-related conditions (invasive cervical cancer,
cervical dysplasia, cancer of the vulva, vagina, anus,
penis, and head and neck, anogenital warts, and RRP) is
estimated to be €528.6 million, with a plausible range of
€480–686 million [11, 12].
Two vaccines (Cervarix and Gardasil) are currently
available and utilized, providing protection against HPV
genotypes 16 and 18. However, there are some differ-
ences between the vaccines. Gardasil, in fact, offers an
additional protection against genotypes 6 and 11, which
actually cause over 90% of anogenital warts and virtually
all cases of RRP in both sexes [7, 8, 13].
Although the efficacy and cost-effectiveness of these
prevention measures have been verified [14–16], no
studies were conducted aimed at quantifying the impact
of HPV-related diseases on women’s health in terms of
mortality and morbidity in Italy. When the mortality
profile is characterized by chronic diseases (second stage
of epidemiological transition [17]), the analysis of mor-
tality no longer suffices for a correct evaluation of popu-
lation’s health. Consequently in a demographic stage,
characterized by an increase in life expectancy and a sig-
nificant growth in chronic pathologies, it is no longer
possible to consider only the standard life table of a
specific population, but it is necessary to analyze the
morbidity profile of the population itself [18–21].
Different demographic tools allow the study of health
and the impact of health care assistance. The life tables
are one of the oldest tools used in demographic analyses
and generally represent the starting points of demo-
graphic studies. The life tables describe the evolution of
mortality in a single cohort of newborns, due to one or
more death causes. However, a cohort may evolve in
multiple death causes or health states (disease). In order
to be investigated, these factors need an evolution of the
traditional life tables. When we want to consider differ-
ent death causes and disease and disability, like in the
evaluation of HPV-prevention strategies, one of the most
widespread methods to estimate life tables is the multi-
state Table [20–23].
The objective of this study is to estimate the impact of
HPV-related diseases on the Italian population, in terms
of health conditions and death risk. Furthermore, it eval-
uates the role of the Italian prevention system on health
improvement, both in terms of mortality and morbidity.
Methods
A multistate life table was developed in order to esti-
mate trajectories of individuals who, in the course of
time and age, move across health states through differ-
ent transition probabilities. The multistate tables are
based on the same assumptions of a Markov process,
therefore:
– The health states considered in the model are
thorough and mutually exclusive.
– The probability to move from one health state to
following states only depends on (is conditioned on)
the health state of the individual at transition time
(memoryless process).
– Transition probabilities are steady over time.
The transition probability from state i to state j in the
age interval x , x + n is initially represented by a central
rate (Mx), and then converted into transition probability
P(x, n), by using the method proposed by Rogers and
Ledent in 1976 [24] and widely shared in the literature
[25–27] (see Additional file 1).
Model structure
The disease evolution considered in the model repre-
sents a combination of the natural history of HPV-
related diseases, with the health care assistance provided
to those patients who may be diagnosed. This model,
unlike what has been done in the literature, assumes that
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the transition probability from the health state to the
other disease states are based on a more pragmatic ver-
sion of the incidence rate (the real world history of the
disease) and not on the virtual incidence rate (the nat-
ural history of the disease). Figure 1 shows a good ap-
proximation of this combination and includes the
possibility for patients to move directly from the health
state (state 1) to one of the considered morbidity states.
For example, it is possible to move from anal and
cervical cancer states (state 5 and 6 respectively) to the
state of death for anal/cervical cancer (state 7 and state
8 in relation to the cause). Finally, depending on the age,
specific mortality risks were applied using Italian life
Tables [28].
Epidemiological data
Once the model structure is defined, it is necessary to
identify the transition probabilities by age among the dif-
ferent states being considered. There are no secondary
data that are referred to HPV-related diseases considered
in this study. However, different studies have been
conducted and provide scientific data concerning the
burden of the disease on the Italian population and the
progression and treatment of the considered diseases
[11, 14]. Specifically, Baio et al. (2012) [11, 12] carried
out a systematic review of the literature that identifies
the prevalence and incidence of the main HPV-related
diseases in Italy. Conversely, Favato et al. [14] developed
a cost-effectiveness model, comparing two alternative
prevention strategies (Screening vs. Screening + quadriva-
lent vaccine) in Italy. Starting from these studies, the
probabilities described in Table 1 have been estimated
considering age, disease state, and cause of death (see
Additional file 1 for detail).
Burden of disease index (DALYs, QALYs, and impact
measures)
Different indicators may estimate the impact of a
chronic disease on women’s health. The most commonly
widespread indicators used in economic evaluations
[29], World Health Organization (WHO) [30, 31] and
the National Institute of Health (ISS) [32] have been uti-
lised in this study.
The quality-adjusted life years (QALY) are a measure
of health widely used in the economic evaluations of
health care interventions [29]. The rationale for this
indicator relies on the term “utility,” indicating the well-
being of an individual using a health care service [33].
According to this assumption, a weight related to the
morbidity lived by the individual is assigned to each
health state. The utility scale of these states is given by
values worth 0 (minimum preference corresponding to
death) and 1 (maximum preference corresponding to
perfect health).
Fig. 1 Markov process multistate tables: transitions at age x – adjustment of conceptual model
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However, recently Marcellusi et al. [34] estimated the
utilities expressed by women and men who lived or are
living HPV-related pathologies, through the Time Trade
Off questionnaire (TTO). The authors interviewed about
60 patients (an ideal number due to the variability of the
detection tool recorded in the validation study [33]), di-
vided by pathological group. Specifically, the inquired
pathological conditions were the following: genital warts,
cervical intraepithelial neoplasia (CIN) grade 1 and 2/3,
cervical and colorectal-anal cancer, head and neck
Table 1 Transition probability by age
Parameter Description and parameters used to estimate transition probabilities Source
Transitions from the health state (State 1)
xλ11 Probability of permanence in healthy state without onset of HPV-related diseases (addition to 1
of the remaining probabilities from state 1) 1 − xλ12 − xλ13 − xλ14 − xλ15 − xλ16 − xλ18
Complementary
probability
xλ12 Probability of genital warts onset = incidence of diagnosis by age in genital warts [11, 14, 59, 63, 64]
xλ13 Probability to contract a CIN 1 = incidence of diagnosis by age of CIN 1 [11, 65–67]
xλ14 Probability to contract a CIN 2/3 = incidence of diagnosis by age of CIN 2/3 [11, 65–67]
xλ15 Probability of cervical cancer onset by age = incidence of cervical cancer by age (assuming
all cancers are diagnosed)
[60]
xλ16 Probability of anal cancer onset by age = incidence of anal cancer by age (assuming all cancers
are diagnosed)
[60, 68]
Transitions from the genital warts state (State 2)
xλ22 Probability of permanence of genital warts by age = Recurrence rate of genital warts by age
between age x − 1 and x
[11, 59, 69]
xλ21 Probability of healing from genital warts = 1 − xλ22 − xλ28 Complementary
probability
Transitions from state of CIN 1 (State 3)
xλ33 Probability of permanence of CIN 1 by age =1 − xλ31 − xλ38 Complementary
probability
xλ34 Transition probability from CIN 1 to CIN 2/3 = progression rate of the disease by age from state
CIN 1 to CIN 2/3
[11, 70]
xλ31 Probability of healing from CIN 1 by age = spontaneous regression rate of the disease by age.
In this case women are only observed and not treated.
[11, 70–72]
Transitions from state of CIN 2/3 (State 4)
xλ44 Probability of permanence in CIN 2/3 =1 − xλ41 − xλ48 Complementary
probability
xλ41 Probability of healing from CIN 2/3 by age = efficacy rate of health care intervention on diagnosed
women (Constant by age)
[11, 70–72]
xλ45 Transition probability from CIN 2/3 to CCU state by age for lack of efficacy of health care
intervention = progression rate of the disease by age
[11, 66, 70–72]
Transitions from Cervical cancer state (State 5)
xλ55 Probability of permanence of CCU state by age = recurrence rate (recurrence of disease) of CCU [73, 74]
xλ51 Probability of healing from cervical cancer state by age = 1 − xλ55 − xλ57−xλ59 Complementary
probability
xλ57 Probability of death from cervical cancer by age for ill subjects =1 − xλ59 − 5 − year survival by age [28, 75]
Transitions from Anal Cancer (State 6)
xλ66 Probability of permanence in CCU state by age = recurrence rate of anal cancer (recurrence of disease) [68]
xλ61 Probability of healing from cervical cancer state by age =1 − xλ66 − xλ67−xλ69 [28, 75]
xλ68 Probability of death from anal cancer by age for ill subjects =1 − xλ69 − 5 − year survival by age Complementary
probability
Transitions to death for other causes (State i - > State 9)
xλi9
i = 1, 2, 3, 4, 5,6
Probability of death by age from any state for other causes except for cervical cancer = Probability
of general death by age
[28]
Legend: i = state of origin; j = state of destination; x = Age group: 0–4, 5–9, 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69,
70–74, 75–79, 80–84, ≥85;
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squamous cell carcinoma (HNSCC), and ano-genital
warts (AWS). Figure 2 reports the results of the esti-
mated utilities only for the diseases considered in the
multi-state model.
The concept of DALY was introduced for the first
time in 1993 by the World Bank in the World Devel-
opment Report [35]. In general, DALYs can be repre-
sented as the sum of years of life lost due to the
mortality caused by a disease (YLL) and the years lost
due to disability (YLD). YLLs correspond to the num-
ber of specific deaths due to cause i, multiplied by
the life expectancy at age of death. As far as the years
lived with disability are concerned, the method is
similar to that used to estimate QALYs. The disability
is measured as the product of the incident cases with
the disease, quality of life of the pathological condi-
tion, and duration of the disease.
In order to estimate the impact of HPV prevention on
population health, specific attribution measures were
estimated [32]. The assumption of these measures is
simple: if behavior (exposure) is associated with a
disease, how would the disease frequency change if the
exposure disappeared? Or, more realistically, if the ex-
posure frequency changed [32]?
In our model the prevention factor is the anti-HPV
vaccine for 12-year-old girls. The attributable risk in
the exposed (RAE) may be estimated as the difference
between the incidence rates in the exposed and unex-
posed. Therefore, RAE represents the fraction of
HPV-related diseases that may be prevented with the
vaccine. A further impact indicator is represented by
the attributable risk in the population (RAP), obtained
by the difference between the incidence in unvaccin-
ated people and the incidence in the population. In
this case, RAP is the number of avoided cases thanks
to the primary prevention (vaccination) implemented
in Italy.
Estimate of effectiveness in vaccination strategies
The parameters available in Italy to be considered for
the implementation of the effectiveness data of the two
vaccines are the following:
1. Vaccination coverage: number of actually vaccinated
subjects with the three doses, on the total of 12-year-
old girls for whom free anti-HPV vaccine is available
in Italy;
2. Number of vaccinated subjects with Bivalent vaccine
(coverage for HPV 16 and 18) and Quadrivalent
vaccine (coverage for HPV 6, 11, 16 and 18);
3. Effectiveness of vaccination on HPV preventable
serotypes;
4. Number of avoided cases thanks to the reduction of
subjects contracting the virus.
With reference to points 1 and 2, a cohort of women
(born in 1998) who benefited from free vaccination in
2008 (when aged 11) has been considered. Therefore,
the results of the model will refer to a fictitious cohort
of women that have experienced the vaccination cover-
age rate and distribution of the two types of vaccination
identical to this cohort. Table 2 summarizes coverage
data and the type of administered vaccination reported
by the ISS [36].
With reference to point 3, the evaluation of vaccine
effectiveness and tolerability has been the object of an
extended and deep clinical research program, involving
about 21,000 women aged between 16 and 26 years, and
over 2500 adolescents aged between 9 and 15 years. In
double-blind, placebo-controlled multicentric studies of
phase II and III, the vaccine administered in three doses
(according to a scheduling of 0, 2, and 6 months) reduced
by 100% (95% confidence intervals [CI]: 91.0–100.0%,
p < 0.001) the development risk of pre-cancerous high-
grade lesions (CIN 2/3) of adenocarcinoma in situ and
Fig. 2 Estimate of utilities by pathological state (mean values and 95% CI) [35]
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invasive cancer, associated with the viral types
included in the vaccine, over a follow-up period of 2–
2.5 years [37–43]. With reference to external genital
lesions (genital warts, vulvar, vaginal grade 1/3
lesions), none of the vaccinated women (n = 2261)
developed such lesions, compared to the 40 recorded
cases out of 2279 women belonging to the placebo
group (p < 0.001) [42].
In order to summarize the effects of vaccination by
age, reference was made to the study of Favato et al. [14]
in which, as previously mentioned, vaccine effectiveness
was projected on HPV-related events. In particular,
based on main clinical randomized trials of the quadri-
valent vaccine [42, 44–48] and the support provided by
a board of clinical experts, the authors projected the ef-
fectiveness of this vaccine on a standard population,
using a Bayesian approach. Furthermore, the authors as-
sumed that the vaccine reduced the transmission of over
10 different types of non-vaccinable HPV (31, 33, 35, 39,
45, 51, 52, 56, 58, 59), causing about 20% of cervical
cancers [49]. As a consequence, the vaccine reduces by
32.5% (95% CI: 6.0–51.9%) the development of pre-
cancerous stages (CIN 2/3), associated with 10 kinds of
non-vaccinable viruses [47, 48]. This effect is defined
cross-protection and has been widely discussed and dem-
onstrated in the literature [47, 48, 50, 51].
Starting from the published model, the reduction
effects of HPV-related events have been extrapolated,
considering a vaccinated cohort and an unvaccinated
one. As reported in Fig. 3, the effectiveness of quadriva-
lent vaccination is distinguished by age. In fact, from the
introduction of the vaccine - 14 years for the first cohort
- we can expect that its effectiveness increases due to
the effects on recurrences and reaches a plateau after
the disease peaks.
Finally, reduction rates of HPV-related events xθij
 
have been applied to transition probabilities from the
health state (state 1) to the genital warts disease states,
CIN 1, CIN 2/3 and CCU:
xλ1 j
Vacc ¼ xλ1j  12π1j  xθ1j for j ¼ 2; 3; 4; 5
where xλ1 j
Vacc represents the transition probability by age
x in the model in which HPV vaccination is considered,
12π1j is the percentage of patients actually vaccinated
and xθ1j is the reduction rate of HPV-related events esti-
mated by the BEST study [14].
Table 2 Distribution of population actually vaccinated by type of vaccine and region – Italy 2009 (cohort 1998) [36]








Valle d’Aosta Bivalent 73.8 483 0 356
Piemonte Quadrivalent 64.6 17,048 11,013 0
Liguria Bivalent 72.8 5625 0 4095
Lombardia Bivalent 64.7 39,751 0 25,719
PA Trento Bivalent 63.4 2534 0 1606
PA Bolzano Quadrivalent 25.5 2534 646 0
Veneto Quadrivalent 74.9 20,297 15,202 0
Friuli VG Quadrivalent 71.7 4546 3259 0
Emilia Romagna Quadrivalent 75.6 15,898 12,019 0
Toscana Bivalent 84.3 13,705 0 11,553
Marche Bivalent 72.7 6379 0 4638
Umbria Bivalent 80.3 3480 0 2794
Lazio Quadrivalent 64.8 23,324 15,114 0
Abruzzo Quadrivalent 73.8 5681 4193 0
Molise Quadrivalent 65.9 1503 990 0
Campania Quadrivalent 62.6 33,223 20,798 0
Basilicata Quadrivalent 82.4 2814 2319 0
Puglia Quadrivalent 81.4 20,848 16,970 0
Calabria Bivalent 69.2 10,294 0 7123
Sicilia Quadrivalent 55.3 26,522 14,667 0
Sardegna Bivalent 84.7 6825 0 5781
TOTAL 263,313 117,190 63,666
Marcellusi Population Health Metrics  (2017) 15:36 Page 6 of 15
With reference to the two types of vaccination, it has
been assumed that the efficacy towards genital warts
only occurs in the proportion of women who submitted
to quadrivalent vaccination. Regarding the anal cancer,
the model assumes that the vaccination effectiveness
was the same of the cervical cancer considering that the
HPV genotypes associated with the two cancers are simi-
lar (HPV 16 and 18) [11, 52].
Sensitivity analysis
In order to verify the uncertainty of the model, a one-
way deterministic sensitivity analysis (DSA) was con-
ducted, changing each parameter with a plausible inter-
val on the main important parameters of the model.
This kind of analysis allowed identification of the param-
eters that mostly influenced the change of the final
estimation of QALYs gained or DALYs lost due to vac-
cination strategy. The definition of possible may vary
from model to model, but normally it is reasonable to
change the parameters according to a plausible interval
or the data available in the literature.
More specifically, the model parameter tested in this
DSA were:
 Screening variation: the model assumes that
cancer screening and management are constant
over time in the base-case. In order to test the
variability on this parameter, a deterministic
sensitivity analysis was performed by simulating a
specific scenario in which the incidence rates of
CIN1/2/3 were higher/lower than the base case
(due to an increment/decrement effect of screening
program ± 20%) and, consequently, this reduce/in-
crease the incidence rate of cervical cancer;
 Vaccine efficacy: ±20% of xθ1jparameter;
 Coverage rate: ±20% of the coverage rate xπ1j;
 Vaccine type: the minimum scenario considers the
vaccination with the only HPV2 vaccine and the
maximum scenario with only HPV4 vaccine;
 Utilities: the minimum scenario considers the utilities
estimated by Baio et al. [52] (lower credibility
interval) and the maximum scenario considers the
utilities considered by Elbasha et al. [53].
Results
Impact of HPV-related diseases on unvaccinated women
The mortality-morbidity table in case of lack of vaccin-
ation was estimated and the main indicators are repre-
sented in Table 3. Specifically, the model outlined that
28 women out of 1000 (28.037 × 100,000 women) live a
HPV-related pathological condition (genital warts, CIN
1, CIN 2/3, CCU and death from CCU). With reference
to life expectancy at birth, a woman following the behav-
ior of the fictitious cohort considered in the model, may
expect to live 83.1 years, of which 1.65 years will be in
one of the HPV-related disease conditions.
Comparing the QALYs lived by the fictitious cohort of
unvaccinated women (82.75 QALYs) with the life expect-
ancy of the same women at birth (83.1 years), the model
concludes that HPV-related diseases cause a burden on
women’s health of 0.35 years of perfect health lost due
to HPV-related diseases. This aspect is represented by
the area between the two curves of Fig. 4 in which the
curves represent, respectively, the years lived by the co-
hort of the table (continuous line) and the QALYs lived
by the same population (red dotted line). As reported in
Fig. 4, the higher decrease of life quality compared to
years lived is observed between 20 and 45 years of age.
In fact, at these ages, the prevalence of HPV-related dis-
eases considered in the model is concentrated. Specifically,
genital warts are the most prevailing conditions (19.894
cases out of 100,000 women) with a higher incidence in
Fig. 3 Effectiveness of vaccination by age and pathological condition – reduction rate of events by age xθij
 
[14]
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younger ages. Pre-cancerous conditions (CIN) later arise,
impacting on the quality of life of women aged between
40 and 50.
The estimated curves of the life years lived with dis-
abilities (YLDs), the years of life lost (YLLs), and the
disability-adjusted life years (DALYs) for the cohort due
to HPV-related diseases considered in the increment-
decrement model are represented in Fig. 5. Specifically,
our model estimated a sharp rise of both DALYs (con-
tinuous curve) and years lived with disability (YLDs)
after 15 years of age. However, even if DALYs decline
after 45 years of age they remain somewhat high due to
Table 3 Main indicators for type of vaccination strategies - fictitious cohort of Italian women with vaccination coverage and vaccine
distribution of 1998 cohort vaccinated in 2009 in Italy (Radix of the Tables 100,000 women) – Year 2012
Health state Subjects per state Lived years per health state Lived QALY per woman Life expectancy at birth by health state
No vaccination
Healthy 71,963 8,146,560 81.466 81.466
Genital warts 19,894 121,849 0.950 1.218
CIN 1 3679 19,458 0.162 0.195
CIN 2/3 3004 18,195 0.147 0.182
Cervical cancer 825 4123 0.024 0.041
CC death 296 – – –
Anal cancer 195 976 0.006 0.010
AC death 145 – – –
Total 100,000 8,311,161 82.754 83.112
Vaccination
Healthy 84,421 8,222,681 82.227 82.227
Genital warts 11,180 69,003 0.538 0.690
CIN 1 2056 10,873 0.090 0.109
CIN 2/3 1682 10,187 0.083 0.102
Cervical cancer 365 1826 0.011 0.018
CC death 131 – – –
Anal cancer 94 471 0.003 0.005
AC death 72 – – –
– – – –
Total 100,000 8,315,042 82.951 83.150
Fig. 4 QALYs lived by the cohort vs. Lived Years (Lx) by age – fictitious cohort of Italian women (table root 100,000 women) – Year 2012
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the impact of the years of life lost. In fact, the higher
prevalence of pathological conditions in the first stage of
women’s life, affects the worsening of quality of life
(genital warts and CIN) and increases the number of
DALYs. However, in the age groups over 40, the years of
lost life due to the disease (cervical cancer and anal can-
cer) keep the number of DALYs lived by the cohort
women high.
Effects of anti-HPV vaccination on women’s health
The burden of HPV-related diseases considering the
women included in the vaccination strategy is reported
in Table 3. On average the model estimates that 15 cases
out of 1000 (15,579 out of 100,000) live a pathological
condition. The years lived with the disease represent
about 1.1% of the total (98,361 out of 8,315,042 years
lived by 100,000 women) and the life expectancy is
83.15 years, of which 0.92 years lived with the disease.
QALYs for vaccinated women are 82.95 (life years lived
in perfect health) and the estimated morbid weight of
HPV-related diseases corresponds to 0.2 QALYs (84.95
QALYs vs. 83.15 years of life expectancy at birth).
Consequently, by comparing the cohort of unvaccinated
women with the cohort of women who may benefit from
the vaccination (Table 4), we obtain 3881 additional years
for 100,000 women. Also, the lifespan lived in a healthy
life would increase by approximately 76,121 years for
100,000 women and by more than 19,000 QALYs. The de-
crease of disability-adjusted life years is of about 6900
DALYs (40% of the decrease due to years of life lost).
Furthermore, as represented in Fig. 6, QALYs gained
by vaccinated women compared to unvaccinated ones
are much higher for women aged 25 to 29 years with a
peak at about 1800 incremental QALYs per 100,000.
However, among women aged more than 40 years, the
model estimates a lower value (about 200 QALYs per
100,000) that also remains constant in the remaining
period. This effect by age is once again explained by the
higher prevalence of genital warts (in numerical terms)
that are more common among young people.
Fig. 5 DALYs lived by the fictitious cohort of Italian women (radix of the Tables 100,000 women) – Year 2012
Table 4 Comparison of main comparison indicators between vaccinated cohort and unvaccinated one – fictitious cohort of Italian
women with vaccination coverage and vaccine distribution of 1998 cohort vaccinated in 2009 in Italy (Radix of the Tables 100,000
women) – Year 2012
Simulations Lived years Healthy life years QALY DALY YLL YLD
Cohort of unvaccinated women (100,000 women) 8,311,161 8,146,560 8,275,447 14,686 5567 9119
Cohort of vaccinated women (100,000 women) 8,315,042 8,222,681 8,295,112 7712 2760 4952
Increases (Vaccinated – Unvaccinated) 3881 76,121 19,665 -6974 -2807 −4167
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The effect of age and genital warts can be also ob-
served in the estimate of avoided DALYs as reported in
Fig. 7. In fact, due to vaccination (represented by the
green dotted line) and the consequently avoided YLD, a
higher rate of disability is prevented in younger ages
(<15 years). In older ages, vaccination contributes to the
number of avoided YLLs and to the health gains in
terms of avoided DALYs (Fig. 7).
Figure 8 summarizes the main impact of the measures
analyzed in the multistate model. In particular, consider-
ing the anti-HPV vaccination as exposure factor, the
model reports a risk of 145 events out of 100,000
women. In other words, assuming 100% vaccination
coverage with maximum efficacy, there will be at least
1.5 cases out of 1000 women that we will not be able to
avoid with prevention. These HPV-related events are
due to the lack of vaccine effectiveness on total HPV
strains that, even if combined, would be highly effective
only in relation to HPV types 6, 11, 16, and 18, and con-
sequently only to part of the considered diseases [11].
However, by comparing this value with the actual cover-
age rate, the model estimates 93 women out of 100,000
that represent the number of cases that could be avoided
if vaccination coverage reached the entire population. In
conclusion, in case of no vaccination, we estimate 265
cases out of 100,000 that could be avoided taking some
preventive measures.
Sensitivity analysis
Figure 9 reports the deterministic sensitivity analysis
(DSA). The figure shows the variation of QALYs gained
and DALYs lost due to the vaccination strategy (difference
Fig. 6 QALYs by the fictitious cohort of Italian women thanks to vaccination (radix of the Tables 100,000 women) – Year 2012
Fig. 7 Avoided DALY by the fictitious cohort of Italian women thanks to vaccination (radix of the Tables 100,000 women) – Year 2012
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Fig. 8 Impact measures of a fictitious cohort of Italian women (risk for 100,000 women) – Year 2012
Fig. 9 Deterministic Sensitivity Analysis results – tornado diagram QALYs (a) and DALYs (b)
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between vaccination scenario results and base case re-
sults) if such parameters were changed in the model
and represents these variation (bar of the figure)
compared to the same outcome in the principal ana-
lysis (y-axis of the graph).
The simulations shows that the most sensible parame-
ters are the utilities associated with the disease states
that have important impacts on both QALYs gained or
DALYs lost due to vaccination strategy (Fig. 9). A vari-
ation in the utilities, as reported in the maximum sce-
nario, decreases the number of QALYs gained from the
base-case of 19,665 to −11,471. Conversely, considering
the minimum scenario with lower utilities for each dis-
ease state, QALYs gained increase by 11.471 QALYs
(42% respect to the base-base) (Fig. 9a). The same vari-
ation would affect the number of DALYs lost with a vari-
ation of approximately 13.000 DALYs for the maximum
scenario and 5.000 DALYs for the minimum (Fig. 9b).
The DSA also shows that the vaccination type plays an
important role on the HPV-related disease impact for
women health. In fact, using the bivalent vaccine only,
the model estimates an increase of “only” 6.620 QALYs
compared to the base-case while the adoption of quadri-
valent vaccine only could increase the number of QALYs
gained vs. the base case of 19.946 years lived in perfect
health.
A variation on the coverage rate, screening, and
vaccine efficacy (± 20% respect to the base case analysis)
showed a lower impact on the number of DALY lost: ±
7%, 6%, and 2% respectively if compared to the base-
case results. The effect predicted to the model for deter-
ministic sensitivity analysis corresponds to a variation of
QALYs gained between ±19% for vaccine efficacy and
±20% for coverage rate while no impact was estimated
for screening variation scenario (± 1% respect to the
base-case analysis).
Discussion
The aim of this model was to evaluate the actual effect
of vaccination on women’s health in Italy. The analysis
projects a fictitious cohort of women in order to evalu-
ate the impact on morbidity and mortality trajectories of
these individuals. Doing so, the study considers the
actual vaccination coverage nationwide, along with the
distribution of different types of vaccines at a regional
level. As we know, the main objective of HPV preven-
tion strategies is usually to reduce the number of
cervical cancers (which are a direct consequence of the
negative evolution of HPV). However, the impact of
HPV on women’s health concerns both the negative
evolution of cervical cancer (to death) and a number of
diseases related to the virus. In addition to mortality, the
model also included the analysis of the morbidity of
HPV-related diseases in order to provide a more
appropriate evaluation of the epidemiological burden of
these pathologies and the possible impact of different
vaccination strategies.
As evidenced by the study, primary prevention plays an
important role in improving women’s health. Anti-HPV
vaccination, in particular, may improve life expectancy,
increase the quality of life, and reduce the disability of
women that have experienced HPV-related diseases.
Comparing the QALYs lived by the fictitious cohort of un-
vaccinated women (82.7 QALYs) with the life expectancy
of the same women at birth (83.1 years), it is possible to
notice that HPV-related diseases cause a burden on
women’s health of 0.35 years of perfect health lost due to
HPV-related diseases.
Different studies were conducted in order to evaluate
the impact of different vaccination strategies in Italy.
Merler and Ajelli (2013) [54] studied the anti-measles
vaccination strategy on the Italian population during the
last century. Similar to our work, the authors developed
an infection transmission model considering a stationary
population with a Markov structure that projects two
scenarios: a) the natural history of the disease (base-
case) and b) a simulation of the effect of vaccination and
coverage rate registered in Italy for the same population.
The Merler and Ajelli (2013) [54] study is similar to our
model for the applied methodology and the perspective
but differs in terms of objective. In fact, their study was
aimed at evaluating the impact of measles on the de-
crease of fertility in Italy from a demographic perspec-
tive while our objective was to evaluate morbidity and
mortality from a demographic perspective.
Guzzetta et al. (2014) [55] tried to estimate the pro-
gression of HPV infection and the clinical consequences
through a mathematical model that considers different
levels of sexual activity under the hypothesis of demo-
graphic equilibrium over time. Also in this case, the au-
thors simulated different cohorts of female population
considering different vaccination strategies. Similarly to
our model, Guzzetta et al. compared a scenario with no
vaccination vs. a 70% coverage rate of 12-year-old vacci-
nated female. In agreement with our results, Guzzetta et
al. estimated a reduction of around 50% of cervical can-
cer cases after 80 years of simulation thanks to HPV vac-
cination. However, in addition to some methodological
aspects that differentiate our work from that of Guzzetta
et al. (multistate static approach vs. dynamic evolution
of different cohort), our study has three main innovative
aspects: a) a greater number of related diseases consid-
ered in the model (cervical cancer vs. cervical cancer,
CIN 1/2/3, anal cancer, and genital warts) that have a
considerable impact in terms of epidemiology and qual-
ity of life, [1, 11, 56] b) a combination of HPV 4 and
HPV 2 vaccine as registered in the different Italian re-
gions with different coverage rates (Guzzetta et al.
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consider the only HPV 2 vaccination with a constant
coverage rate equal to 70%), and c) the chance to con-
sider not only the disease event avoided but also the dis-
ease impact in terms of quality of life, disability, and
avoided risk thanks to the primary prevention adopted
in Italy in the previous years.
In the previous literature, the economic perspective
has been frequently adopted for the evaluation of the
impact of the HPV-related diseases. For example, the
study of Favato et al. [14], simulates a different cohort of
female population in Italy. However, also in this case,
the model refers to HPV 4 vaccine only and considers
results in terms of cost avoided and QALYs without any
estimation in terms of expectancy, disability, or impact
on life expectancy in good health. Indeed, the main ob-
jective of all models cited before was to project the virus
effects on the female population. In our model, the
estimation is based on diagnosis rate registered in the
Italian population and estimation of the morbidity-
mortality life table, considering the risk variation gener-
ated by the prevention strategy. The second approach
represents a simplification of the real infectious disease
progression but considers the most reliable data avail-
able relating to the diagnosis rate and not only the hypo-
thetical natural history of the virus [57].
Some consideration about the economic consequences
of our model is also warranted. Considering constant
risk over time, we can estimate that in Italy the HPV
vaccination strategy could reduce yearly cervical cancer
cases from 3000 [11] to 1400 (considering the reduction
estimated from our model). This reduction might have a
positive impact in terms of quality of life and life expect-
ancy and in terms of economic resources. In fact, we
can estimate a yearly cost reduction of over €38 million
(assuming a mean cost per treated case equal to €24.286
[11, 58]). Considering also the pre-cancerous disease
state, we can estimate additional €10 million generated
by the reduction of the 28,000 [11] yearly cases in
Italy to around 16,400 cases of CIN 1/2/3. Finally, of
the 62,000 genital warts estimated in Italy each year
[11] the vaccination strategy could avoid over 37,000
cases per year generating a cost reduction of add-
itional €18 million [11].
Obviously, this study has different limitations that
have to be taken into account. First of all, currently
available data are not always referred to national inci-
dence data. They often refer to registry data distributed
nationwide (AIRTUM Cancer Registry) or to previously
published epidemiological data (BEST study to estimate
effectiveness) [11, 12, 14, 59, 60]. However, as of today,
there are no registry data of HPV-related events and not
all morbid events may have a virological origin.
The second limitation relies on the limited dimension
of the model. HPV causes a high number of related
diseases (cancer of the vulva, vagina, head and neck, etc)
[1, 4, 9, 53]. Conversely, the model only considers a lim-
ited number of pathological states that consequently
underestimate the real impact of HPV-related diseases
and the effects of vaccination on Italian women’s health.
The last limitation is related to the methodological as-
sumptions used with reference to transition probabilities.
In fact, the model uses an approach for contemporaries
on a longitudinal tool [18, 20, 61], assuming that the co-
hort of individuals recorded in a single year behaves like
the generation of vaccinated women. Furthermore, the
simplifying assumption of linearity (concerning survi-
vors) and uniform distribution of the events between a
specific age and the following one (for example, deaths)
should be taken into account. Finally, always considering
the estimate method of transition probabilities, the model
does not take into account competing risks [20, 23, 62]
that may underestimate the real risks of mortality for
individuals who avoid disease and death events thanks to
vaccination.
Conclusion
In conclusion, this work is a first attempt to evaluate the
actual effect of vaccination on women’s health in Italy by
including several HPV-related diseases in addition to cancer
morbidity. In our opinion, the model represents a useful
tool for measuring the effects of health care intervention
on a population, particularlyin the long term. In fact, from
this perspective, the impact of HPV vaccination strategies
may increase, by affecting the vaccination coverage and the
inclusion of males in vaccination programs, but also by
developing secondary prevention strategies.
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